A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

September 29, 2025

Study Completion Date

September 29, 2025

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

DRUG

VX-407

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (1)

ICON Lenexa, Lenexa

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY